SynRx Therapeutics completes RMB 100M+ Series A to advance its DDR-targeted drug platform and clinical-stage pipeline

Recently, SynRx Therapeutics, an innovative drug discovery company focused on precision oncology and next-generation therapeutics targeting the DNA damage response (DDR) pathway, announced the completion of a Series A financing round exceeding RMB 100 million. This round was led by the Zhejiang Provincial "4+1" Biomedical and High-end Medical Device Industry Fund, with co-investment from multiple institutions including Lapam Capital, Haibang Venture Capital, Long Yield Venture Capital, and the Hangzhou Talent Fund. The proceeds will be primarily used to accelerate the clinical development of SYN818 and SYN608, and to support the ongoing advancement of SynRx's proprietary drug discovery platform in the field of DNA damage response. StartPointAdvisors acted as the exclusive financial advisor for this transaction.

SynRx Therapeutics has consistently focused on addressing unmet clinical needs in the DNA damage response (DDR) field since its inception. In the post-PARP inhibitor era, the company has developed several globally innovative small molecule drugs targeting key areas such as combination therapies with standard regimens, overcoming drug resistance, and expanding into new indications.

The company's lead product, SYN818, is a novel, potent, and highly selective DNA Polymerase Theta (Polθ) inhibitor. It works by precisely disrupting the DNA damage repair mechanism in tumor cells, thereby selectively inducing tumor cell death. As the first Chinese drug candidate targeting this mechanism to enter Phase Ib clinical trials, SYN818 is currently being evaluated in combination with Olaparib for its safety, tolerability, pharmacokinetic profile, and antitumor efficacy in patients with locally advanced or metastatic solid tumors harboring BRCA mutations and/or homologous recombination repair pathway deficiencies. Furthermore, Polθ inhibitors hold broad potential for combination with various treatment modalities, including radiotherapy, chemotherapy, antibody-drug conjugates (ADCs), and radiopharmaceuticals, promising to deliver safer and more effective therapeutic options for different types of cancer patients in the future.

Another candidate, SYN608, is a highly active and selective PARG inhibitor positioned as a potential "best-in-class" therapy. The drug is currently in Phase I clinical trials, actively exploring its therapeutic potential in patients who have developed resistance to PARP inhibitors, as well as in those with indications for which no approved treatments currently exist.